multiferon süstelahus
swedish orphan biovitrum international ab - alfainterferoon - süstelahus - 3000000rÜ 0.5ml 0.5ml 6tk
ciprinol infusioonilahuse kontsentraat
krka, d.d., novo mesto - tsiprofloksatsiin - infusioonilahuse kontsentraat - 10mg 1ml 10ml 5tk
amoxicillin sandoz 250mg/5ml suukaudse suspensiooni pulber
sandoz pharmaceuticals d.d. - amoksitsilliin - suukaudse suspensiooni pulber - 50mg 1ml 60ml 1tk
budiair inhalatsiooniaerosool, lahus
chiesi pharmaceuticals gmbh - budesoniid - inhalatsiooniaerosool, lahus - 200mcg 1annus 200annus 1tk
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
ciprofloxacin norameda infusioonilahus
norameda uab - tsiprofloksatsiin - infusioonilahus - 2mg 1ml 100ml 10tk; 2mg 1ml 200ml 10tk
amoxicillin krka dispergeeruv tablett
krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 1000mg 8tk; 1000mg 16tk; 1000mg 12tk; 1000mg 20tk; 1000mg 6tk
amoxicillin krka dispergeeruv tablett
krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 750mg 30tk; 750mg 12tk; 750mg 16tk; 750mg 20tk